Literature DB >> 16044666

A potassium channel, the M-channel, as a therapeutic target.

Toral S Surti1, Lily Y Jan.   

Abstract

Compounds that stimulate or inhibit M-channels (ie, voltage-gated potassium channels formed by KCNQ2, KCNQ3 and KCNQ5) have been evaluated in clinical trials for epilepsy, stroke and Alzheimer's disease. The importance of M-channel function in reducing neuronal excitability is underscored by the finding that KCNQ2/3 mutations causing mild reduction of M-channel activity are linked to neonatal epilepsy. M-channel openers decrease the hyperexcitability responsible for epileptic seizures, neuropathic pain and migraine. Conversely, M-channel blockers may enhance cognitive functions. The M-channel has thus emerged as a promising target for treating epilepsy, stroke, migraine, pain, dementia, anxiety and bipolar disorder.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16044666

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  16 in total

1.  Polarized axonal surface expression of neuronal KCNQ channels is mediated by multiple signals in the KCNQ2 and KCNQ3 C-terminal domains.

Authors:  Hee Jung Chung; Yuh Nung Jan; Lily Y Jan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-30       Impact factor: 11.205

Review 2.  Modification of K+ channel-drug interactions by ancillary subunits.

Authors:  Glenna C L Bett; Randall L Rasmusson
Journal:  J Physiol       Date:  2007-12-20       Impact factor: 5.182

3.  Loss of AKAP150 perturbs distinct neuronal processes in mice.

Authors:  Brian J Tunquist; Naoto Hoshi; Eric S Guire; Fang Zhang; Karin Mullendorff; Lorene K Langeberg; Jacob Raber; John D Scott
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-18       Impact factor: 11.205

Review 4.  Molecular underpinnings of ventral surface chemoreceptor function: focus on KCNQ channels.

Authors:  Daniel K Mulkey; Virginia E Hawkins; Joanna M Hawryluk; Ana C Takakura; Thiago S Moreira; Anastasios V Tzingounis
Journal:  J Physiol       Date:  2015-02-19       Impact factor: 5.182

5.  Chemical control of metabolically-engineered voltage-gated K+ channels.

Authors:  Zhengmao Hua; Anatoli Lvov; Trevor J Morin; William R Kobertz
Journal:  Bioorg Med Chem Lett       Date:  2011-04-28       Impact factor: 2.823

6.  Hyper-SUMOylation of the Kv7 potassium channel diminishes the M-current leading to seizures and sudden death.

Authors:  Yitao Qi; Jingxiong Wang; Valerie C Bomben; De-Pei Li; Shao-Rui Chen; Hao Sun; Yutao Xi; John G Reed; Jinke Cheng; Hui-Lin Pan; Jeffrey L Noebels; Edward T H Yeh
Journal:  Neuron       Date:  2014-09-03       Impact factor: 17.173

7.  Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions.

Authors:  Zhaobing Gao; Tangzhi Zhang; Meng Wu; Qiaojie Xiong; Haiyan Sun; Yinan Zhang; Liansuo Zu; Wei Wang; Min Li
Journal:  J Biol Chem       Date:  2010-06-28       Impact factor: 5.157

8.  Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance.

Authors:  Alexander R Mackie; Lioubov I Brueggemann; Kyle K Henderson; Aaron J Shiels; Leanne L Cribbs; Karie E Scrogin; Kenneth L Byron
Journal:  J Pharmacol Exp Ther       Date:  2008-02-13       Impact factor: 4.030

9.  Clinical utility of adjunctive retigabine in partial onset seizures in adults.

Authors:  Konrad Rejdak; Jarogniew J Luszczki; Barbara Błaszczyk; Roman Chwedorowicz; Stanislaw J Czuczwar
Journal:  Ther Clin Risk Manag       Date:  2012-01-20       Impact factor: 2.423

10.  Transcriptional control of KCNQ channel genes and the regulation of neuronal excitability.

Authors:  Mariusz Mucha; Lezanne Ooi; John E Linley; Pawel Mordaka; Carine Dalle; Brian Robertson; Nikita Gamper; Ian C Wood
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.